Goeltz II Robert C. 4

What Happened

• Robert C. Goeltz II, Chief Financial Officer of Arcus Biosciences (RCUS), was granted a total of 120,000 shares-equivalent on January 23, 2026: 24,000 shares reported as acquired and 96,000 reported as derivative (restricted stock units). Both entries show a $0.00 price because these were awards/RSU grants, not market purchases.

Key Details

• Transaction date: 2026-01-23; Form 4 filed: 2026-01-26 (filed timely).
• Grants: 24,000 shares (A) and 96,000 derivative shares (A) — total 120,000.
• Price: $0.00 per share (award/RSU, not an open-market trade); no immediate cash value reported in the Form 4.
• Shares owned after the transaction: not specified in the supplied details of this summary.
• Footnotes from the filing:
  • F1: The RSUs vest in four equal annual installments beginning December 15, 2026, subject to continued service.
  • F2: References the unvested portion of the Reporting Person's RSU grants.
  • F3: Notes an option becomes exercisable in 48 equal monthly installments after January 1, 2026 (included in the filing disclosures).
• No indication this was a sale or a cashless exercise; it is a compensation award.

Context

• These awards are time-based RSUs subject to multi-year vesting, so they are not immediately liquid and do not represent an open-market purchase or sale. Such grants are typical executive compensation and do not by themselves indicate an insider buying or selling for investment reasons.